{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T03:11:49Z","timestamp":1773285109229,"version":"3.50.1"},"reference-count":21,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T00:00:00Z","timestamp":1622678400000},"content-version":"unspecified","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Trauma Surg Acute Care Open"],"accepted":{"date-parts":[[2021,5,19]]},"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Organism susceptibilities for trauma-associated pneumonia (TAP) differ from those in other patient populations, including the critically ill. The purpose of this study was to identify common organisms and their susceptibilities in the respiratory isolates of trauma patients diagnosed with pneumonia within the first 7\u2009days of hospital admission, and to create a TAP-specific disease-state antibiogram to guide empiric antibiotic therapy in this patient population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study was a retrospective review of adult trauma patients with pneumonia admitted between September 1, 2015 and August 31, 2018. Patients included were diagnosed with and treated for pneumonia, with respiratory cultures drawn within the first 7 hospital-days; both culture-positive and culture-negative patients were included. Subgroup antibiograms were made for diagnosis made on days 1\u20133, 4\u20135, and 6\u20137.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were 131 patients included with a median age of 45; 85% were male, and 31% were illicit drug users. Most patients (63%) had ventilator-associated pneumonia, and most respiratory samples (77%) were obtained via bronchoalveolar lavage. Cultures were positive in 109 patients and negative in 22. There were 144 total isolates; 54% were Gram-negative bacteria. The most common Gram-negative pathogens were<jats:italic>Haemophilus influenzae<\/jats:italic>(16%) and<jats:italic>Klebsiella pneumoniae<\/jats:italic>(15%). The most common Gram-positive pathogen was<jats:italic>Staphylococcus aureus<\/jats:italic>; methicillin-resistant<jats:italic>S. aureus<\/jats:italic>(MRSA) constituted 8% of all isolates. With culture-negative patients counted as susceptible, ceftriaxone monotherapy and ceftriaxone+vancomycin susceptibilities were 85% and 94%, respectively. Susceptibilities to cefazolin, ampicillin\/sulbactam, cefepime, piperacillin\/tazobactam, and levofloxacin were 49%, 69%, 91%, 90%, and 92%, respectively. Illicit drug use and day of pneumonia diagnosis did not appreciably affect antibiotic susceptibilities.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>For TAP diagnosed within the first 7\u2009days of hospital admission, ceftriaxone monotherapy is adequate as empiric therapy, including in ventilated patients. The addition of vancomycin can be considered in patients with MRSA risk factors or who are critically ill.<\/jats:p><\/jats:sec><jats:sec><jats:title>Level of evidence<\/jats:title><jats:p>Level III, prognostic and epidemiological.<\/jats:p><\/jats:sec>","DOI":"10.1136\/tsaco-2020-000602","type":"journal-article","created":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T16:42:44Z","timestamp":1622738564000},"page":"e000602","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Narrowing antibiotic spectrum of activity for trauma-associated pneumonia through the use of a disease-specific antibiogram"],"prefix":"10.1136","volume":"6","author":[{"given":"Michelle H","family":"Ting","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J","family":"Radosevich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0585-9389","authenticated-orcid":false,"given":"Jordan A","family":"Weinberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4076-5748","authenticated-orcid":false,"given":"Michael D","family":"Nailor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,6,3]]},"reference":[{"key":"2024051311450407000_6.1.e000602.1","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.1991.01410250105017"},{"key":"2024051311450407000_6.1.e000602.2","doi-asserted-by":"publisher","DOI":"10.1086\/511159"},{"key":"2024051311450407000_6.1.e000602.3","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw504"},{"key":"2024051311450407000_6.1.e000602.4","doi-asserted-by":"publisher","DOI":"10.1097\/TA.0b013e3181e4d7be"},{"key":"2024051311450407000_6.1.e000602.5","doi-asserted-by":"publisher","DOI":"10.1097\/TA.0b013e3181f9fb51"},{"key":"2024051311450407000_6.1.e000602.6","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-007-0729-5"},{"key":"2024051311450407000_6.1.e000602.7","doi-asserted-by":"publisher","DOI":"10.1089\/sur.2010.052"},{"key":"2024051311450407000_6.1.e000602.8","unstructured":"CLSI 2014 Performance standards for antimicrobial susceptibility testing; Twenty-Fourth informational supplement. CLSI document M100-S24 Wayne, PA Clinical and Laboratory Standards Institute"},{"key":"2024051311450407000_6.1.e000602.9","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00040-06"},{"key":"2024051311450407000_6.1.e000602.10","first-page":"1314","article-title":"Antibiotic susceptibility and molecular analysis of invasive Haemophilus influenzae in Canada, 2007 to 2014","volume":"72","author":"Tsang","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2024051311450407000_6.1.e000602.11","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01794-12"},{"key":"2024051311450407000_6.1.e000602.12","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.9.2.274"},{"key":"2024051311450407000_6.1.e000602.13","first-page":"23","article-title":"Beyond susceptible and resistant, part I: treatment of infections due to gram-negative organisms with inducible \u03b2-lactamases","volume":"16","author":"Macdougall","year":"2011","journal-title":"J Pediatr Pharmacol Ther"},{"key":"2024051311450407000_6.1.e000602.14","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0b013e328343eb33"},{"key":"2024051311450407000_6.1.e000602.15","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ijantimicag.2016.03.005","article-title":"Evaluation of a disease state management guideline for urinary tract infection","volume":"47","author":"Zmarlicka","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"2024051311450407000_6.1.e000602.16","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw118"},{"key":"2024051311450407000_6.1.e000602.17","first-page":"861","article-title":"Utility of ampicillin-sulbactam for empiric treatment of ventilator-associated pneumonia in a trauma population","volume":"69","author":"McMillian","year":"2010","journal-title":"J Trauma"},{"key":"2024051311450407000_6.1.e000602.18","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1089\/sur.2011.056","article-title":"Locally derived versus guideline-based approach to treatment of hospital-acquired pneumonia in the trauma intensive care unit","volume":"13","author":"Becher","year":"2012","journal-title":"Surg Infect"},{"key":"2024051311450407000_6.1.e000602.19","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-115-8-585"},{"key":"2024051311450407000_6.1.e000602.20","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01083-07"},{"key":"2024051311450407000_6.1.e000602.21","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e318287f713"}],"container-title":["Trauma Surgery &amp; Acute Care Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/tsaco-2020-000602","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T18:45:20Z","timestamp":1715625920000},"score":1,"resource":{"primary":{"URL":"https:\/\/tsaco.bmj.com\/lookup\/doi\/10.1136\/tsaco-2020-000602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,6,3]]},"published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1136\/tsaco-2020-000602"],"URL":"https:\/\/doi.org\/10.1136\/tsaco-2020-000602","relation":{},"ISSN":["2397-5776"],"issn-type":[{"value":"2397-5776","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6]]}}}